默克将以66亿美元出售非专利药业务

　　German drug maker Merck KGaA announced Sunday that it is selling its generic drug business to Mylan Laboratories Inc. of the U.S. for $6.6 billion.

　　The deal frees Darmstadt-based Merck to concentrate on its core pharmaceutical and chemical activities， while allowing Mylan， a generic drug maker based in Canonsburg， Pa.， to expand its global reach.

　　Merck said that the two companies "signed a share purchase agreement whereby Mylan will acquire all Merck Generics companies throughout the world" and it expects the transaction — which requires regulatory approval — to close in the second half of 2007.

　　Merck said the unit had sales of $2.4 billion and an operating profit of more than $500 million last year.

　　德国制药公司默克公司上周日宣布，将把旗下的非专利药业务以66亿美元的价格出售给美国非专利药生产企业Ｍｙｌａｎ公司。

　　通过出售旗下非专利药业务，默克将能更加集中精力于核心药品和化学制品业务，而Ｍｙｌａｎ则可以借此扩充自己的产品线和全球市场份额。

　　默克称，两家公司已经达成一份股份收购协议，Ｍｙｌａｎ将收购默克在全球范围内的所有非专利药公司。目前这一交易还有待相关监管机构批准，预计收购行动有望在今年下半年完成。

　　默克称，该公司的非专利药部门去年实现销售收入24亿美元，营业利润5亿美元。